News

Pfizer only offered to discount six products through the Most Favored Nation program, and healthcare policy experts suggest the real-world impact remains uncertain.

SCAN Health Plan will expand its 2026 Medicare Advantage benefits with $0 copays and higher dental, vision and allowance coverage amid funding and coverage cuts from larger insurers such as UnitedHealthcare and Aetna.

Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now accounting for 21% of Medicare Advantage enrollees, with recent growth driven by chronic condition SNPs surpassing dual-eligible SNPs due to changing CMS requirements, according to a new KFF report.

In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand to Judi Health and how it reflects broader trends in technology-driven, transparent PBMs.

As part of the Most Favored Nation pricing effort, Pfizer has agreed to invest in U.S. manufacturing and to allow access to its drugs at a discount through a new direct-to-patient website.

Changes in eye blood vessels signal early risk for Alzheimer’s disease, offering a noninvasive biomarker for early detection and intervention.

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition.

Insulin will be available through Sanofi’s Insulins Valyou Savings Program starting January 1, 2026.

Here’s what you missed this week on Managed Healthcare Executive.

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year old.

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy changes effectively.

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more than 1 million Americans.

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing uncompensated care costs.

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer program that began earlier this month.

FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA.

Yael Bensoussan, M.D., director of the University of South Florida Health Voice Center, discusses menopause-related voice changes and how artificial intelligence is being used to address them.

Carbapenemase-producing Enterobacterales (CRE) surge in the U.S., with New Delhi metallo-β-lactamase (NDM) becoming a major public health threat.

The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.

Data quality issues and increased rates of claim denials provide opportunities for artificial intelligence to make improvements, according to a recent survey by Experian Health.

Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance employee wellbeing and control expenses.

Brian K. Lee, Ph.D., of Drexel University Dornsife School of Public Health, says that despite the fact that some studies suggest there is link between acetaminophen use during pregnancy and neurodevelopmental disorders, there is a lack of evidence to support that conclusion.

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.

Here’s what you missed this week on Managed Healthcare Executive.

Opzelura gains FDA approval as the first topical JAK inhibitor for children with atopic dermatitis, offering a steroid-free treatment option.